Role of oxaliplatin in the treatment of colorectal cancer.

Ther Clin Risk Manag · 2009 · PMC2697505 · PMID 19436599

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

of borderline significancep = 0.064so close (0.05 < p ≤ 0.1)

46 The combination regimen increased both the complete (1.2% vs 0.6%) and partial RR (44.4% vs 35.1%), but the difference was of borderline significance (p = 0.064).

also in 1,677 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.